ophthalmology

Quarterly Questions is the new gold standard for board certificationDr. Mali discusses how the Quarterly Questions program assesses fundamental (“walking around”) knowledge needed in the everyday practice of ophthalmology (40 questions annually), as well as the application of information from five journal articles (10 questions annually).
Biologic products increase dry eye optionsMany new diagnostic tools are available for dry eye and ocular surface disease (OSD). Treatments for dry eye and OSD have mixed results, however, said Bennie H. Jeng, MD.
Four ocular surface health questions to consider before cataract surgeryA thorough investigation of ocular surface health and initiation of any necessary treatment is the first step toward successful cataract surgery.
Surveying the artificial tear landscapePatients use artificial tears for different reasons and diverse conditions. While available products supplement tear production and provide relief, few distinctions between drops have been clearly established. Recent studies show that direct comparison of a new product to an older, established one and use of “real-world” metrics can be most useful to prescribers.
The role of ophthalmologists in the opioid epidemicAn observational cohort study, published in JAMA Ophthalmology, used Medicare Part D data to assess the number of opioid prescriptions written by ophthalmologists in the United States.
Fillers 101: Foundations for successThe foundations for success in using fillers during oculofacial surgery include understanding the characteristics of these products, which influences outcomes, and learning techniques to avoid and treat complications.
Facial shaping with fillers an ‘artform’
USPSTF finalizes recommendation on vision screening in childrenDespite a lack of consensus on the importance of screening infants for vision problems, there is proof that screening preschoolers can catch serious problems and allow for corrections to prevent permanent vision loss.
European Commission approves adalimumab for paediatric uveitisThe European Commission has approved adalimumab (Humira, AbbVie) as the first biologic treatment for chronic non-infectious anterior uveitis in paediatric patients from 2 years of age who have had an inadequate response to conventional therapy.
NC ODs say laser privileges will expand access to care